Supplemental Table 1

Revisiting the pharmacodynamics uroselectivity of Alpha1-Adrenergic Receptor Antagonists

Bruna Maria Castro Salomão Quaresma, Amanda Reis Pimenta, Anne Caroline Santos da Silva, André Sampaio Pupo, Luiz Antonio S. Romeiro, Claudia Lucia Martins Silva and François Noël*

Journal of Pharmacology and Experimental Therapeutics

Table 1: K_i values of the five FDA-approved α_1-AR antagonists for binding to the three human transfected α_1-AR subtypes: overview of literature data.

	***K*$_i$ (nM)**								
α_{1A}	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Tamsulosin	0.012	0.019	0.13	0.04	-	0.63	0.20	-	0.19
Silodosin	0.039	0.036	-	0.20	-	-	-	-	0.44
Alfuzosin	-	-	-	11.5	-	100	10.0	6.31	-
Terazosin	-	-	-	4.90	-	126	-	6.92	8.71
Doxazosin	--	-	-	-	1.99	6.31	3.16	2.75	-
α_{1D}									
Tamsulosin	0.03	0.06	0.18	0.14		0.63	0.16	-	0.05
Silodosin	2.2	2.0	-	5.13		-	-	-	8.71
Alfuzosin	-	-	-	1.99		10.0	3.16	3.98	-
Terazosin	-	-	-	2.57		12.6	-	3.47	1.35
Doxazosin	-	-	-	-	1.66	7.94	3.98	1.66	-
α_{1B}									
Tamsulosin	0.12	0.29	1.92	0.47	-	7.94	1.26	-	0.63

Silodosin	6.5	21	-	5.13	-	-	-	-	10.2
Alfuzosin	-	-	-	1.70	-	12.6	10.0	2.95	-
Terazosin	--	-		2.40	-	12.6	-	1.95	0.46
Doxazosin	-	-	-	-	0.72	6.31	1.00	1.05	-

(1): Tatemichi et al. 2006; (2) Shibata et al., 1995; (3): Kuo et al., 2000; (4) Sato et al., 2012; (5): Hatano et al. 1996; (6): Richardson et al., 1997, (7) Kenny et al., 1996, (8) Forray et al., 1994 (new nomenclature), (9) Ishiguro et al., 2002.